Combining HIV prevention Options with Mental health service delivery for Adolescent girls and young women (CHOMA): results of a pilot hybrid effectiveness-implementation randomized trial in South Africa

IF 4.9 1区 医学 Q2 IMMUNOLOGY
Jennifer Velloza, Nomhle Ndimande-Khoza, Lisa Mills, Nicole Poovan, Aliza Adler, Elizabeth B. Sherwin, Carrie Mathew, Zinhle Sokhela, Ruth Verhey, Dixon Chibanda, Monica Gandhi, Connie Celum, Sinead Delany-Moretlwe
{"title":"Combining HIV prevention Options with Mental health service delivery for Adolescent girls and young women (CHOMA): results of a pilot hybrid effectiveness-implementation randomized trial in South Africa","authors":"Jennifer Velloza,&nbsp;Nomhle Ndimande-Khoza,&nbsp;Lisa Mills,&nbsp;Nicole Poovan,&nbsp;Aliza Adler,&nbsp;Elizabeth B. Sherwin,&nbsp;Carrie Mathew,&nbsp;Zinhle Sokhela,&nbsp;Ruth Verhey,&nbsp;Dixon Chibanda,&nbsp;Monica Gandhi,&nbsp;Connie Celum,&nbsp;Sinead Delany-Moretlwe","doi":"10.1002/jia2.70037","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Introduction</h3>\n \n <p>Adolescent girls and young women (AGYW) at risk of HIV frequently have symptoms of common mental disorders (CMDs), which are associated with lower pre-exposure prophylaxis (PrEP) adherence. We conducted a pilot hybrid effectiveness-implementation trial (CHOMA) to evaluate whether an evidence-based mental health intervention adapted for PrEP delivery (“Youth Friendship Bench SA”) could address CMD and PrEP adherence among South African AGYW.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>CHOMA was conducted in Johannesburg from April 2023 to February 2024. We enrolled AGYW (18−25 years) who were already on or willing to initiate PrEP and had CMD symptoms (Self-Reporting Questionnaire 20-item [SRQ-20]≥7). Participants were randomized to our Youth Friendship Bench SA intervention (five problem-solving sessions with a lay counsellor, one group session) or standard-of-care CMD services (brief CMD assessment, referral). Counselling sessions occurred at enrolment and Weeks 2, 4, 8 and 12. Co-primary outcomes were PrEP adherence (positive result on a urine tenofovir assay) and reduced CMD symptoms (SRQ-20&lt;7) at Week 12 and, secondarily, Week 4. We used Poisson regression to assess intervention effects and summarized responses to three validated scales assessing intervention acceptability, appropriateness and feasibility (ranges: 1–4).</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Of 116 AGYW enrolled, the median SRQ-20 score was 9. We retained 69% through Week 12. Of 57 intervention participants, 64.9% (<i>N</i> = 37) received four or more sessions. At Week 4, 29/36 (80.6%) participants in the intervention and 25/41 (61.0%) in the standard-of-care had recent PrEP use (RR = 1.40; 95% CI = 1.03−1.89; <i>p</i> = 0.03), but this was not sustained through Week 12 (RR = 0.88; 95% CI = 0.64−1.22; <i>p</i> = 0.44). Enrolment SRQ-20 score was not associated with Week 12 PrEP adherence or retention. CMD symptoms did not differ by arm at Week 4 or 12, although the proportion with SRQ-20 scores &gt;7 decreased overall between Weeks 4 (54.5%, 42/77) and 12 (35.0%, 28/80; <i>p</i> = 0.02). Median acceptability, appropriateness and feasibility scores were 3.50, 3.75 and 3.25, respectively.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>The intervention improved PrEP adherence at Week 4, although the effect was not durable to Week 12, possibly due to retention challenges. Reductions in CMD symptoms were seen in both arms. Findings suggest different mental health and PrEP support interventions may be needed to improve integrated service delivery among AGYW.</p>\n </section>\n </div>","PeriodicalId":201,"journal":{"name":"Journal of the International AIDS Society","volume":"28 9","pages":""},"PeriodicalIF":4.9000,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jia2.70037","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the International AIDS Society","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jia2.70037","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction

Adolescent girls and young women (AGYW) at risk of HIV frequently have symptoms of common mental disorders (CMDs), which are associated with lower pre-exposure prophylaxis (PrEP) adherence. We conducted a pilot hybrid effectiveness-implementation trial (CHOMA) to evaluate whether an evidence-based mental health intervention adapted for PrEP delivery (“Youth Friendship Bench SA”) could address CMD and PrEP adherence among South African AGYW.

Methods

CHOMA was conducted in Johannesburg from April 2023 to February 2024. We enrolled AGYW (18−25 years) who were already on or willing to initiate PrEP and had CMD symptoms (Self-Reporting Questionnaire 20-item [SRQ-20]≥7). Participants were randomized to our Youth Friendship Bench SA intervention (five problem-solving sessions with a lay counsellor, one group session) or standard-of-care CMD services (brief CMD assessment, referral). Counselling sessions occurred at enrolment and Weeks 2, 4, 8 and 12. Co-primary outcomes were PrEP adherence (positive result on a urine tenofovir assay) and reduced CMD symptoms (SRQ-20<7) at Week 12 and, secondarily, Week 4. We used Poisson regression to assess intervention effects and summarized responses to three validated scales assessing intervention acceptability, appropriateness and feasibility (ranges: 1–4).

Results

Of 116 AGYW enrolled, the median SRQ-20 score was 9. We retained 69% through Week 12. Of 57 intervention participants, 64.9% (N = 37) received four or more sessions. At Week 4, 29/36 (80.6%) participants in the intervention and 25/41 (61.0%) in the standard-of-care had recent PrEP use (RR = 1.40; 95% CI = 1.03−1.89; p = 0.03), but this was not sustained through Week 12 (RR = 0.88; 95% CI = 0.64−1.22; p = 0.44). Enrolment SRQ-20 score was not associated with Week 12 PrEP adherence or retention. CMD symptoms did not differ by arm at Week 4 or 12, although the proportion with SRQ-20 scores >7 decreased overall between Weeks 4 (54.5%, 42/77) and 12 (35.0%, 28/80; p = 0.02). Median acceptability, appropriateness and feasibility scores were 3.50, 3.75 and 3.25, respectively.

Conclusions

The intervention improved PrEP adherence at Week 4, although the effect was not durable to Week 12, possibly due to retention challenges. Reductions in CMD symptoms were seen in both arms. Findings suggest different mental health and PrEP support interventions may be needed to improve integrated service delivery among AGYW.

Abstract Image

将艾滋病毒预防方案与向少女和年轻妇女提供精神卫生服务(CHOMA)相结合:在南非进行的一项混合效果-实施随机试验的结果
面临艾滋病毒感染风险的少女和年轻妇女(AGYW)经常出现常见精神障碍(cmd)症状,这与暴露前预防(PrEP)依从性较低有关。我们进行了一项混合有效性实施试验(CHOMA),以评估一种基于证据的心理健康干预措施(“青年友谊长凳SA”)是否适用于PrEP的实施,可以解决南非AGYW的CMD和PrEP依从性问题。方法于2023年4月至2024年2月在约翰内斯堡进行CHOMA检查。我们招募了已经开始或愿意开始PrEP并有CMD症状的AGYW(18 - 25岁)(自我报告问卷20项[SRQ-20]≥7)。参与者被随机分配到我们的青年友谊长凳SA干预(五次与外行咨询师一起解决问题的会议,一次小组会议)或标准护理CMD服务(简短的CMD评估,转诊)。咨询课程在入学和第2、4、8和12周进行。共同的主要结果是PrEP依从性(尿替诺福韦检测阳性)和在第12周和第4周减少CMD症状(SRQ-20<7)。我们使用泊松回归来评估干预效果,并总结了对评估干预可接受性、适当性和可行性的三个有效量表的反应(范围:1-4)。结果116例AGYW入组,SRQ-20中位数为9分。第12周我们的留存率为69%。在57名干预参与者中,64.9% (N = 37)接受了4次或更多的治疗。在第4周,29/36(80.6%)的干预参与者和25/41(61.0%)的标准护理参与者最近使用过PrEP (RR = 1.40; 95% CI = 1.03 - 1.89; p = 0.03),但这种情况没有持续到第12周(RR = 0.88; 95% CI = 0.64 - 1.22; p = 0.44)。入组SRQ-20评分与第12周PrEP依从性或保留无关。在第4周和第12周,不同组的CMD症状没有差异,尽管SRQ-20评分为>;7的比例在第4周(54.5%,42/77)和第12周(35.0%,28/80,p = 0.02)之间总体下降。可接受性、适宜性和可行性得分中位数分别为3.50、3.75和3.25。结论干预提高了第4周的PrEP依从性,尽管效果不能持续到第12周,可能是由于保留挑战。两组CMD症状均有所减轻。研究结果表明,可能需要不同的心理健康和PrEP支持干预措施来改善老年妇女之间的综合服务提供。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of the International AIDS Society
Journal of the International AIDS Society IMMUNOLOGY-INFECTIOUS DISEASES
CiteScore
8.60
自引率
10.00%
发文量
186
审稿时长
>12 weeks
期刊介绍: The Journal of the International AIDS Society (JIAS) is a peer-reviewed and Open Access journal for the generation and dissemination of evidence from a wide range of disciplines: basic and biomedical sciences; behavioural sciences; epidemiology; clinical sciences; health economics and health policy; operations research and implementation sciences; and social sciences and humanities. Submission of HIV research carried out in low- and middle-income countries is strongly encouraged.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信